Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resected Stage Clear all
Completed Phase 3 Interventional Results available

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

NCT01667419
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • California City, California • Hayward, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

NCT00242918
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, ZD1839
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

NCT04743310
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
tozuleristide, Canvas imaging system, Surgical resection of tumor
Drug · Device · Procedure
Lead sponsor
John Yu
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 4 Interventional Results available

Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants

NCT00859547
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
rThrombin, 1000 IU/mL
Biological
Lead sponsor
ZymoGenetics
Industry
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 22, 2026, 5:55 PM EDT
Withdrawn Phase 2 Interventional

S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer

NCT00084435
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, docetaxel, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Los Angeles, California • Decatur, Illinois • Springfield, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Phase 2 Interventional

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

NCT05638698
View directory record Official record
Conditions
Pancreas Cancer
Interventions
TG01 Vaccine, QS-21, Balstilimab
Biological · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

NCT00002752
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
iodine I 131 monoclonal antibody 81C6
Radiation
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

NCT03405155
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Nivolumab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106
View directory record Official record
Conditions
Stage IB-IIIA Non-small Cell Lung Carcinoma
Interventions
AZD9291 80 mg/40 mg, Placebo AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
View directory record Official record
Conditions
Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early Stage
Interventions
TAS6417, Zipalertinib Matching-placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
30
States / cities
Anchorage, Alaska • Duarte, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers

NCT00660699
View directory record Official record
Conditions
Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
Interventions
Gemcitabine, Docetaxel, Radiation
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

NCT01274338
View directory record Official record
Conditions
Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
1,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 580 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 3 Interventional

Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy

NCT01568346
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

NCT04047303
View directory record Official record
Conditions
Astrocytoma, Glioblastoma
Interventions
CC-90010
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas

NCT01502605
View directory record Official record
Conditions
Astrocytoma, Glioma
Interventions
5-Aminolevulinic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients

NCT00576446
View directory record Official record
Conditions
Malignant Glioma
Interventions
Dendritic cell Vaccine
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Not listed Phase 1 Interventional

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

NCT00986661
View directory record Official record
Conditions
Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer
Interventions
PV-10 (10% rose bengal disodium)
Drug
Lead sponsor
Provectus Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Tampa, Florida • Bethlehem, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Phase 2 Interventional

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

NCT02008656
View directory record Official record
Conditions
Rectal Cancer
Interventions
Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy
Drug · Radiation · Behavioral + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
26
States / cities
Irvine, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Recruiting Not applicable Interventional

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

NCT05839912
View directory record Official record
Conditions
Melanoma
Interventions
Excision of clinically detected lymph node metastasis before any systemic therapy, Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Procedure
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

NCT01553019
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton radiation, Gemcitabine
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Vinblastine and Methotrexate in Treating Children With Desmoid Tumors

NCT00003019
View directory record Official record
Conditions
Desmoid Tumor
Interventions
methotrexate, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 1 Interventional

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00290719
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Intradialytic Drug Removal by Short-daily Hemodialysis

NCT00596167
View directory record Official record
Conditions
End Stage Renal Disease, Infection
Interventions
Intravenous antibiotics
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 22, 2026, 5:55 PM EDT
Not listed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor

NCT00107367
View directory record Official record
Conditions
Metastatic Cancer
Interventions
conventional surgery, intraoperative radiation therapy
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 22, 2026, 5:55 PM EDT